Sub: Outcome of Board Meeting held on Monday, November 14, 2022
Ref.: Regulation 30 & 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
With reference to the captioned subject, we Zota Health Care Limited (the "Company") would like to inform you that the Board of Directors of the Company in its Meeting held on Monday, November 14, 2022 at 11:00 A.M. at the registered office of the Company situated at Zota House, 2/896, Hira Modi Street, Sagrampura, Surat - 395002, Gujarat, have inter alia, discussed and approved the following business:
1. Considered and approved standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2022 along with the Limited Review Reports thereon. Financial Results and Limited Review Reports are enclosed herewith (Annexure - 1).
The unaudited standalone and consolidated financial results for the period as aforementioned shall be available on the website of the Stock Exchange where the shares of the Company are listed i.e. at www.nseindia.comand on Company's website at www.zotahealthcare.com
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Zota Health Care Ltd. published this content on 14 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 November 2022 08:01:05 UTC.
Zota Health Care Limited is an India-based drug development, manufacturing and marketing company. The Company manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over the counter (OTC) products. The Companyâs business model comprises three verticals, namely Domestic, Exports and Retail Pharmacy Chain (Davaindia). Its Marketing business vertical involves the direct distribution of generic drugs, OTC products, and other pharmaceutical products through the Companyâs distribution network across India. It has a portfolio of more than 3,000 products in various categories, such as generics, OTC products, allopathic, ayurvedic and others. In the Retail Pharmacy Chain business vertical, it operates a chain of pharmacy stores under the brand Davaindia. Its domestic products include AMLOTOZ AT Tab, APIXACEED 2.5 Tab, APIXACEED 5 Tab, ATRONA 10 Tab, ATRONA 20 Tab, ATRONA 40 Tab, ATRONA ASP 75 Cap, ATRONA ASP 150 Cap, ATRONA ASP 20/75 Cap, ATRONA FB Tab and others.
ZOTA HEALTH CARE LIMITED 